Clinical Trials Browser

Active not recruiting × AZD 6244 × Clear all

NCT01089101 2026-03-18

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Phase 1/2 Active not recruiting

Astrocytoma, Neurofibromatosis 1

NCT01364051 2026-03-18

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Phase 1 Active not recruiting

Melanoma

NCT02407405 2026-03-05

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Phase 2 Active not recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT01362803 2026-03-02

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

Phase 1/2 Active not recruiting

99 enrolled 3 FDA

Neurofibromatosis 1, Pain, Neurofibroma, Plexiform

NCT05101148 2026-02-23

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

Phase 1 Active not recruiting

Neurofibromatosis 1

NCT02143466 2026-01-30

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Phase 1 Active not recruiting

Advanced Non Small Cell Lung Cancer

NCT04590235 2026-01-30

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Phase 1 Active not recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03392246 2026-01-22

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04924608 2026-01-12

KOMET

Phase 3 Active not recruiting

145 enrolled 17 charts 1 FDA

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02546661 2025-12-29

BISCAY

Phase 1 Active not recruiting

Muscle Invasive Bladder Cancer

NCT05309668 2025-12-18

SPRINKLE

Phase 1/2 Active not recruiting

36 enrolled 37 charts

Neurofibromatosis 1

NCT02151084 2025-12-16

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

Phase 2 Active not recruiting

Gastrointestinal

Gallbladder Neoplasms, Recurrence

NCT00463814 2025-11-13

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

Phase 1 Active not recruiting

Neoplasms

NCT00600496 2025-11-13

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT03162627 2025-10-14

Selumetinib and Olaparib in Solid Tumors

Phase 1 Active not recruiting

Breast Neoplasms

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT03944772 2025-01-30

ORCHARD

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02299999 2025-01-15

SAFIR02_Breast

Phase 2 Active not recruiting

Breast Neoplasms